stockrow
Friday 6 November 2026
Export BLLN’s income statement to Excel — free account
BillionToOne, Inc.
BLLN Healthcare Diagnostics & Research
BillionToOne, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $305.1 million, up 100.0% from fiscal 2024.
- Revenue
- +47.2%
- EPS
- +164.3%
- Free cash flow
- +9.25%
- Total debt
- +60.6%
Quarter to September 2026, against a year earlier
111.96
1.93
−1.69%
Follow BLLN
Alert me
BillionToOne, Inc. (BLLN) Net income
BillionToOne, Inc.'s net income for fiscal 2025 was $7.5M, compared with −$41.6M in fiscal 2024. Over the twelve months to 30 September 2026 it was $49.4M. BillionToOne, Inc. ranks 18th of 49 Diagnostics & Research companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $7.5M | — |
| FY2024 | −$41.6M | — |
| FY2023 | −$82.7M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $17.4M | 115.93% |
| Jun 2026 | $8.1M | (55.18%) |
| Mar 2026 | $18.0M | 200.65% |
| Dec 2025 | $6.0M | 4.66% |
| 5 more quarters | Free account |
Net income against peers
| Company | Net income |
|---|---|
| QGEN QIAGEN N.V. compare | $409.3M |
| SHC Sotera Health Company compare | $173.5M |
| CDNA CareDx, Inc. compare | $128.6M |
| VCYT Veracyte, Inc. compare | $126.8M |
| BLLN BillionToOne, Inc. | $49.4M |
| RDNT RadNet, Inc. compare | $19.3M |
| NEO NeoGenomics, Inc. compare | −$32.3M |
| ADPT Adaptive Biotechnologies Corporation compare | −$70.7M |
| GRAL GRAIL, Inc. compare | −$406.2M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on BLLN
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Shares outstanding
- Book value per share
- The full statement